A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes

Course Description

In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.

Scroll to Top